Question special
Chief Resident

I think we are all very impressed by how robust the response was in this phase of the trial. This drug definitely can bring the hope of reaching cholesterol goals and with that, the survival benefits for patients that were not able to otherwise achieve it. I was wondering what the next steps are moving forward and what are some of the things that you would be working on before this could be introduced to clinical practice?